Castle Biosciences, Inc.

Castle Biosciences Beats on EPS, Stock Up 1.7%

Castle Biosciences reported a narrower-than-expected loss per share, which led to a positive stock reaction, with shares rising by 1.7%. However, there was no revenue reported or guidance provided, leaving investors with limited insights into future performance. The slight beat on EPS may indicate some operational efficiencies or cost management.